<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-86483" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rivaroxaban</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Rajshree</given-names>
          </name>
          <aff>Mercy Catholic Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Emmady</surname>
            <given-names>Prabhu D.</given-names>
          </name>
          <aff>UNC school of Medicine, Atrium Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajshree Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabhu Emmady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-86483.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rivaroxaban is used to treat and manage venous thromboembolism as a postoperative thromboprophylaxis for patients undergoing orthopedic surgery to prevent stroke in patients with non-valvular atrial fibrillation and recently has received approval as an add-on drug for secondary prevention of acute coronary syndrome and peripheral arterial disease. It is a novel oral anticoagulant (NOAC) and is commonly referred to as a blood thinner agent. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of rivaroxaban therapy in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients with venous and arterial thromboembolism (VTE) and its related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications of rivaroxaban therapy.</p></list-item><list-item><p>Describe the mechanism of action of rivaroxaban.</p></list-item><list-item><p>Outline the contraindications in a patient on rivaroxaban therapy.</p></list-item><list-item><p>Review the importance of interprofessional team coordination and communication in treating and managing rivaroxaban therapy for patients requiring anticoagulation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=86483&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=86483">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-86483.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rivaroxaban is a novel oral anticoagulant (NOAC) drug. It has several FDA-approved and off-label clinical uses.&#x000a0;</p>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In 2011 the&#x000a0;FDA approved rivaroxaban&#x000a0;for patients undergoing elective orthopedic surgery like knee and hip replacement surgery postoperative thromboprophylaxis of DVT.</p>
          </list-item>
          <list-item>
            <p>In 2011 the FDA approved its use in primary and secondary stroke prevention in people with cardiac arrhythmia, most commonly in nonvalvular Atrial fibrillation.</p>
          </list-item>
          <list-item>
            <p>In 2012, the FDA approved rivaroxaban for treatment after an acute venous thromboembolism event and recurrence of blood clots.</p>
          </list-item>
          <list-item>
            <p>In 2017 the FDA approved the use of rivaroxaban to reduce the continued risk of venous thromboembolism</p>
          </list-item>
          <list-item>
            <p>In 2018, the FDA approved it for secondary prevention after acute coronary syndrome (ACS) or peripheral arterial disease (PAD) as an add-on to clopidogrel and aspirin therapy after&#x000a0;stabilization with initial management<xref ref-type="bibr" rid="article-86483.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>In 2019, the FDA approved rivaroxaban for hospitalized adult patients with an acute medical illness at risk for thromboembolic complications due to restricted mobility and other risk factors.</p>
          </list-item>
        </list>
        <p>
<bold>Other Off-label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>treatment of acute heparin-induced thrombocytopenia as initial therapy in hemodynamically stable patients or following initial therapy with a parenteral non-heparin anticoagulant.<xref ref-type="bibr" rid="article-86483.r2">[2]</xref><xref ref-type="bibr" rid="article-86483.r3">[3]</xref><xref ref-type="bibr" rid="article-86483.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Post-percutaneous coronary intervention with stent placement&#x000a0;(after stabilization with initial management) in patients with nonvalvular atrial fibrillation<xref ref-type="bibr" rid="article-86483.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Acute, symptomatic superficial vein thrombosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-86483.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Rivaroxaban&#x000a0;was the first orally dosed, direct Factor Xa inhibitor, a&#x000a0;small-molecule oxazolidinone derivative. It binds directly and reversibly to Factor Xa via the S1 and S4 pockets.<xref ref-type="bibr" rid="article-86483.r6">[6]</xref>&#x000a0;Rivaroxaban competitively inhibits Factor Xa, demonstrating more than 10,000-fold selectivity for Factor Xa than other related serine proteases. It does not require any cofactors (such as antithrombin) to exert its anticoagulant effect.<xref ref-type="bibr" rid="article-86483.r6">[6]</xref>&#x000a0;This activity prevents the progression of the coagulation cascade through the final common pathway, preventing thrombin generation.&#x000a0;The factor Xa is active in circulating and clot-bound forms. Unlike indirect Factor Xa inhibitors like fondaparinux or heparin,&#x000a0;rivaroxaban&#x000a0;inhibits both free and clot-bound Factor Xa and prothrombinase activity, thereby prolonging clotting times.<xref ref-type="bibr" rid="article-86483.r7">[7]</xref>&#x000a0;</p>
        <p>Metabolism of this drug occurs in the liver via oxidative degradation catalyzed by CYP3A4/5 and CYP2J2 mechanism.</p>
        <p>Excretion occurs mainly via urine 66% and party via feces 28%.</p>
      </sec>
      <sec id="article-86483.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Rivaroxaban is administered orally with&#x000a0;a half-life of 5 to 9 hours (maybe longer in older individuals [e.g., 11 to 13 hours]).<xref ref-type="bibr" rid="article-86483.r8">[8]</xref><xref ref-type="bibr" rid="article-86483.r9">[9]</xref>&#x000a0;The dose ranges from 2.5 mg&#x000a0;twice daily to 20 mg&#x000a0;once daily and does not require monitoring. Rivaroxaban is highly protein-bound. Dosing is generally at a fixed dose without monitoring, and there is no established therapeutic range for the drug.</p>
        <p>The dose for the common indications of rivaroxaban is:</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-valvular Atrial Fibrillation - Stroke prophylaxis:&#x000a0;20 mg once daily with the evening meal</p>
          </list-item>
          <list-item>
            <p>Acute VTE treatment:&#x000a0;15 mg twice daily with food&#x000a0;for three weeks; then 20 mg once daily with food&#x000a0;</p>
          </list-item>
          <list-item>
            <p>VTE primary prevention:&#x000a0;10 mg once daily, with or without food</p>
          </list-item>
        </list>
        <p>Patients with&#x000a0;renal impairment&#x000a0;are at higher risk of thrombosis and bleeding than those with normal&#x000a0;renal&#x000a0;function.<xref ref-type="bibr" rid="article-86483.r10">[10]</xref>&#x000a0;Rivaroxaban&#x000a0;is not recommended for VTE prophylaxis, treatment, or secondary prevention in individuals with&#x000a0;ESRD on dialysis and a creatinine clearance &#x0003c;30 mL/minute. In patients with CrCl &#x0003e;50 mL/minute, No dosage adjustment is necessary. In the patient with moderate renal impairment, dose adjustments are as follows:&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment and prevention of recurrence of VTE:&#x000a0;15 mg twice daily (with food) for 21 days, followed by 20 mg once daily (with food)
<list list-type="bullet"><list-item><p>If therapy continues for more than six months, the dose can be reduced to 10 mg once daily.&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>VTE prophylaxis in surgical patients:&#x000a0;15 mg twice daily (with food) for 21 days, followed by 20 mg once daily (with food). If therapy continues for more than six months, the dose can be reduced to 10 mg once daily. The&#x000a0;duration varies from 12 days to 35 days, depending on the type of surgery.</p>
          </list-item>
          <list-item>
            <p>Thromboprophylaxis in acutely ill medical patients: 10 mg once daily<xref ref-type="bibr" rid="article-86483.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Stroke prevention in non-valvular atrial fibrillation:&#x000a0;20 mg once daily with the evening meal (CrCl &#x0003e;50 mL/minute); or 15 mg once daily with the evening meal (CrCl &#x02264;50 mL/minute)<xref ref-type="bibr" rid="article-86483.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>The drug should not be used in individuals with significant hepatic impairment (Child-Pugh Class B and C with coagulopathy). The use of rivaroxaban has not been studied in children younger than 18 years.</p>
        <p>While switching to rivaroxaban,</p>
        <list list-type="bullet">
          <list-item>
            <p>If previously on warfarin, discontinue warfarin and start rivaroxaban as soon as INR &#x0003c;3&#x000a0;<xref ref-type="bibr" rid="article-86483.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>If previously on low molecular weight heparin, start rivaroxaban 0 to 2 hr before the next scheduled evening administration and omit administration of the other anticoagulant</p>
          </list-item>
          <list-item>
            <p>If previously on unfractionated heparin continuous infusion, then stop infusion and start rivaroxaban at the same time.</p>
          </list-item>
        </list>
        <p>Rivaroxaban should be stopped&#x000a0;at least 24 hr before the surgical procedure.&#x000a0;In patients with a BMI &#x0003e;40 kg/m&#x000a0;or weight &#x0003e;120 kg, the International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of rivaroxaban due to the lack of clinical data in this population.&#x000a0;If used in a patient with a BMI &#x0003e;40 kg/m&#x000a0;or weight &#x0003e;120 kg, ISTH suggests measuring peak and trough levels using an anti-factor Xa assay or mass spectrometry.<xref ref-type="bibr" rid="article-86483.r13">[13]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-86483.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects, according to incidence and severity, are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003e;10%:&#x000a0;Hemorrhage (5% to 28%); major hemorrhage (&#x02264;4%)- including intracranial, GI, retinal, epidural hematoma, adrenal bleeding - have been reported.&#x000a0;By far, the most common complication is bleeding, and risk factors for bleeding include bacterial endocarditis, underlying congenital or acquired bleeding disorders, vascular retinopathy, thrombocytopenia, recent procedure/surgery, stroke, neuraxial procedures, uncontrolled hypertension, renal impairment, recent major bleeding, concomitant use of other drugs that affect hemostasis, and advanced age. Clinical evaluation is&#x000a0;necessary for any unexplained decrease in hemoglobin or blood pressure.</p>
          </list-item>
          <list-item>
            <p>1% to 10%:
<list list-type="bullet"><list-item><p>Central nervous system: Dizziness (2%), insomnia (2%), fatigue (1%), depression (1%), anxiety (1%), and syncope (1%)</p></list-item><list-item><p>Dermatologic: Wound secretion (3%), pruritus (2%), and skin blister (1%)</p></list-item><list-item><p>Gastrointestinal: Abdominal pain (3%)</p></list-item><list-item><p>Hepatic: Increased serum transaminases to &#x0003e;3 x ULN (2% <xref ref-type="bibr" rid="article-86483.r14">[14]</xref>)</p></list-item><list-item><p>Neuromuscular &#x00026; skeletal: Back pain (3%), limb pain (2%), and muscle spasm (1%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Other rare effects:&#x000a0;Bronchiectasis and pulmonary hemorrhage</p>
          </list-item>
          <list-item>
            <p>&#x0003c;1% (discovered in postmarketing and/or reported cases): Agranulocytosis, anemia, anaphylaxis, anaphylactic shock, angioedema, cerebral hemorrhage, cholestasis, DRESS syndrome, injection site hematoma, hemiparesis, hemophthalmos, hepatic injury, hypersensitivity, and Stevens-Johnson syndrome, intracranial hemorrhage, jaundice, retroperitoneal hemorrhage, subdural hematoma, and thrombocytopenia</p>
          </list-item>
        </list>
        <p>
<bold>US Boxed Warning</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased risk of thrombotic events can occur with premature cessation of rivaroxaban, so when discontinuing the drug for reasons besides pathological bleeding or completing the course of therapy, the addition of alternative anticoagulant therapy should merit consideration.</p>
          </list-item>
          <list-item>
            <p>Spinal or epidural hematomas may occur with a spinal puncture or neuraxial anesthesia (epidural or spinal anesthesia)&#x000a0;procedures. The risk of spinal/epidural hematoma increases with indwelling epidural catheters, concomitant use of other drugs that may affect hemostasis in patients with a history of epidural or spinal punctures, or patients with a history of spinal deformity or spinal surgery. Assessment of risks versus benefits is necessary for patients who are anticoagulated or pharmacologic&#x000a0;anticoagulation is anticipated before neuraxial procedures. The optimal timing between the administration of rivaroxaban and neuraxial procedures is unknown.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-86483.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Major Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Allery:&#x000a0;</bold>Severe hypersensitivity to rivaroxaban (or any component of the formulation) can occur.</p>
          </list-item>
          <list-item>
            <p><bold>Hematologic:</bold> Active pathological bleeding is a contraindication for rivaroxaban use.</p>
          </list-item>
        </list>
        <p>
<bold>Other Contraindications are Drug-disease Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Antiphospholipid syndrome:</bold>&#x000a0;this drug is not recommended in patients with triple-positive antiphospholipid syndrome because its safety and efficacy profile is yet to be established. "Triple positive" lupus anticoagulant patients may have increased rates of recurrent thrombotic events on rivaroxaban compared with vitamin K antagonist therapy.</p>
          </list-item>
          <list-item>
            <p><bold>Hepatic impairment:</bold>&#x000a0;Avoid rivaroxaban in patients with moderate to severe hepatic impairment (Child-Pugh classes B and C) or in patients with coagulopathy related to liver disease.<xref ref-type="bibr" rid="article-86483.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Renal impairment:</bold>&#x000a0;Caution is necessary&#x000a0;for patients with moderate renal impairment (CrCl 30-50 mL/minute) and those with worsening renal function. For DVT/PE and VTE prophylaxis, avoid use in patients with CrCl &#x0003c;30 mL/minute. Clinicians should discontinue the drug in patients who develop acute renal failure. If the CrCl declines to &#x0003c;50 mL/min, reduce the rivaroxaban dose from 20 mg to 15 mg.<xref ref-type="bibr" rid="article-86483.r11">[11]</xref>&#x000a0;If the CrCl falls below 15 mL/min, discontinue rivaroxaban.<xref ref-type="bibr" rid="article-86483.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Rivaroxaban is not recommended for patients with atrial fibrillation with end-stage CKD or on hemodialysis&#x000a0;with CrCl &#x0003c;15 mL/min.&#x000a0;<xref ref-type="bibr" rid="article-86483.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Valvular disease:</bold>&#x000a0;Rivaroxaban is not recommended in patients with prosthetic heart valves or rheumatic heart disease and should be avoided in patients with mechanical valves or moderate to severe mitral stenosis.</p>
          </list-item>
          <list-item>
            <p><bold>Patients with increased bleeding risk</bold>:&#x000a0;Congenital or acquired bleeding disorders,&#x000a0;Uncontrolled severe arterial hypertension,&#x000a0;Active ulcerative GI disease, vascular retinopathy, and bronchiectasis or history of pulmonary bleeding<xref ref-type="bibr" rid="article-86483.r11">[11]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Drug-drug interactions:</bold> Potentially significant interactions may exist which require dose or frequency adjustment, additional monitoring, and/or consideration of alternative therapy. Consult a drug-interaction database for more detailed information.&#x000a0;DOACs like rivaroxaban interact with potent CYP3A inhibitors and&#x000a0;P-glycoprotein (P-GP) inhibitors, and&#x000a0;breast cancer resistance protein Bcrp (ABCG2) inhibitors (mainly comprising azole-antimycotics, apart from fluconazole and HIV protease inhibitors), which are multi-pathway inhibitors of rivaroxaban clearance and elimination.<xref ref-type="bibr" rid="article-86483.r15">[15]</xref>&#x000a0;Its use should also be avoided when using other anticoagulants like unfractionated heparin, low molecular weight heparins (e.g., enoxaparin), fondaparinux, warfarin, apixaban, or dabigatran, except when switching therapy to or from rivaroxaban. Rivaroxaban should be combined with simultaneous use with ASA plus clopidogrel (or other thienopyridines, such as ticlopidine or prasugrel) or plus another adenosine diphosphate (ADP) P2Y12 receptor antagonists (such as ticagrelor) should be avoided.<xref ref-type="bibr" rid="article-86483.r11">[11]</xref></p>
        <p><bold>During pregnancy and lactation:</bold>&#x000a0;The limited available evidence raises concern regarding embryo-fetal safety, with a high incidence of miscarriages and a 4% rate of anomalies when using&#x000a0;rivaroxaban. Not enough data are available to judge the safety and efficacy of&#x000a0;using&#x000a0;DOACs during&#x000a0;pregnancy.<xref ref-type="bibr" rid="article-86483.r16">[16]</xref>&#x000a0;Rivaroxaban is&#x000a0;not recommended for breastfeeding women due to the scarce availability of data on the effects of this drug&#x000a0;via lactation to infants&#x000a0;resulting from&#x000a0;drug transfer through breastmilk. However, some studies show that the&#x000a0;RIDs of&#x000a0;rivaroxaban&#x000a0;did not exceed 10% of the maternal dose, suggesting that exposure to&#x000a0;rivaroxaban&#x000a0;via breastfeeding is seldom clinically relevant for the infant. A pediatric assessment of the infant found no detectable drug-related adverse effects. Further studies are necessary to elucidate the impact on breastfeeding infants by exposure to&#x000a0;rivaroxaban.<xref ref-type="bibr" rid="article-86483.r17">[17]</xref>&#x000a0;</p>
        <p><bold>Elderly patients</bold> tend to have higher rivaroxaban concentrations than younger patients (primarily due to reduced clearance).&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Beers Criteria:</bold> The Beers Criteria lists rivaroxaban as a potentially inappropriate medication and to be used with caution in treating VTE or atrial fibrillation in patients &#x02265;75 years due to an increased risk of GI bleeding compared to warfarin and reported rates of other direct oral anticoagulants when used for long-term treatment of VTE or atrial fibrillation (Beers Criteria [AGS 2019]). The risk-benefit ratio of DOACs in elderly patients on polypharmacy should always merit careful consideration.<xref ref-type="bibr" rid="article-86483.r18">[18]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-86483.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before initiating this drug, laboratory tests&#x000a0;are necessary to assess and document coagulation status, including platelet count, activated partial thromboplastin time (aPTT), prothrombin time (PT), and bleeding time. Also, as a baseline and for potential dose adjustment in the event of renal or hepatic insufficiency, liver function tests and serum creatinine should be measured. Routine coagulation testing is&#x000a0;not necessary for rivaroxaban. Assessment of renal function and CBC before initiation, when clinically indicated, and at least annually is essential in all patients.<xref ref-type="bibr" rid="article-86483.r19">[19]</xref>&#x000a0;</p>
        <p>There are several clinical settings in which obtaining a drug level is desired. These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Emergent bleeding or surgery</p>
          </list-item>
          <list-item>
            <p>Checking adherence to appropriate therapy</p>
          </list-item>
          <list-item>
            <p>Continued thrombosis despite therapy</p>
          </list-item>
          <list-item>
            <p>Patients in the extremes of weight and age &#x000a0;</p>
          </list-item>
        </list>
        <p>Although this drug does not require frequent monitoring, drug levels influence decisions about the timing of surgery among preoperative patients.<xref ref-type="bibr" rid="article-86483.r20">[20]</xref>&#x000a0;In most outpatients, levels were within the expected ranges and affirmed current management.<xref ref-type="bibr" rid="article-86483.r20">[20]</xref>&#x000a0;In a small number of patients with breakthrough thrombosis or bleeding, identifying drug levels below or above expected concentrations led to a change in the anticoagulant regimen.<xref ref-type="bibr" rid="article-86483.r20">[20]</xref>&#x000a0;</p>
        <p>The drug levels are relatively predictable for a given dose, and there is no established therapeutic range. Currently, there are no FDA-approved calibration reagents or assays available to measure the drug level. The sensitivity of PT/aPTT is dependent on the laboratory performing the testing and the reagents utilized, although ultimately, the PT/aPTT is not reliably sensitive enough to detect the presence of rivaroxaban. Prolonged PT/aPTT should be assumed to be due to drug effect until proven otherwise. PT (measured with a reagent sensitive to rivaroxaban) may be useful for confirming the absence or presence of an anticoagulant effect (if the blood sampling time is known) when anti-factor Xa assays are not available.<xref ref-type="bibr" rid="article-86483.r11">[11]</xref><xref ref-type="bibr" rid="article-86483.r21">[21]</xref></p>
        <p>If available, the preferred test for ruling out clinically significant serum concentrations and quantifying the anticoagulant effect is anti-factor Xa activity calibrated specifically for rivaroxaban (undetectable anti-Xa activity likely excludes clinically relevant drug concentrations). The International Council for Standardization in Haematology provides examples of rivaroxaban drug levels for the 20 mg once-daily dose, with an expected mean peak of approximately 249 to 270 ng/mL and an expected mean trough of approximately 26 to 44 ng/mL (Gosselin 2018).&#x000a0;An anti-factor Xa assay calibrated for low molecular weight heparin can help rule out clinically relevant drug concentrations, but this is not useful for quantification (ACC <xref ref-type="bibr" rid="article-86483.r22">[22]</xref>; AHA <xref ref-type="bibr" rid="article-86483.r19">[19]</xref>; Leung 2019).</p>
      </sec>
      <sec id="article-86483.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Patients with minor bleeding are managed conservatively, and a single dose of anticoagulation is skipped or delayed.<xref ref-type="bibr" rid="article-86483.r23">[23]</xref>&#x000a0;Patients with major bleeding receive initial management with antifibrinolytic agents like tranexamic acid, or&#x000a0;epsilon-aminocaproic acid has off-label usage as a hemostatic agent in major NOAC-associated bleeds, but currently, there is not enough data on its efficacy.&#x000a0;For patients with life-threatening&#x000a0;bleeding associated with direct factor Xa inhibitor anticoagulation, andexanet alfa&#x000a0;or an unactivated 4-factor PCC can be used.<xref ref-type="bibr" rid="article-86483.r24">[24]</xref>&#x000a0;</p>
        <p>Activated oral charcoal could also be considered if the ingestion occurred within 1 to 2 hours of presentation.</p>
        <p><bold>Andexanet alfa</bold> is an antidote for rivaroxaban. Andexanet alfa is a modified human factor Xa decoy protein. It binds and sequesters factor Xa inhibitors and has a half-life of approximately 1 hour.<xref ref-type="bibr" rid="article-86483.r7">[7]</xref>&#x000a0;The FDA approved andexanet in May of 2018 to reverse anticoagulation by rivaroxaban&#x000a0;in patients with life-threatening or uncontrolled bleeding. Administration of andexanet alfa in such patients is done only after other hemostatic measures (e.g., antifibrinolytic therapy [e.g., tranexamic acid or aminocaproic acid] and drug removal with activated charcoal) are ineffective&#x000a0;or&#x000a0;when patients have an imminent risk of death from bleeding (used in conjunction with other hemostatic measures)&#x000a0;or&#x000a0;for those who need emergent surgery.<xref ref-type="bibr" rid="article-86483.r25">[25]</xref></p>
        <p><bold>Prothrombin complex concentrate (PCC)</bold>&#x000a0;is a mixture of 3 or 4 coagulation factors and can be used off-label to reverse NOACs.<xref ref-type="bibr" rid="article-86483.r23">[23]</xref>&#x000a0;3-factor PCCs contain factors II, IX, and X, whereas 4-factor PCCs contain factors II, IX, X, and VII, along with proteins C and S. There are two types of PCC; inactivated and activated. The only Activated 4 factor PCC&#x000a0;approved for use in the US is Factor VIII inhibitor activity bypassing agent [FEIBA]), which can be used in cases of Factor Xa inhibitor-associated bleeding.<xref ref-type="bibr" rid="article-86483.r26">[26]</xref>&#x000a0;Current guidelines call for a dose of 50 U/kg if using 4-factor prothrombin complex concentrate (4F-PCC).<xref ref-type="bibr" rid="article-86483.r27">[27]</xref>&#x000a0;Rivaroxaban significantly prolonged the prothrombin time, and&#x000a0;endogenous thrombin potential normalized with&#x000a0;PCC.<xref ref-type="bibr" rid="article-86483.r28">[28]</xref>&#x000a0;Fresh frozen plasma is not used to reverse the anticoagulant effects of rivaroxaban. Recombinant activated factor VIIa is also not used to reverse the anticoagulant effect of oral Factor Xa inhibitors.&#x000a0;</p>
        <p>Both PCC and andexanet alfa have the potential to cause thrombosis, which provides the rationale for only using it in cases of severe or life-threatening bleeding. Although some PCC products may also contain coagulation inhibitors such as heparin, antithrombin, protein C, protein S, and protein Z to mitigate thrombotic risk.<xref ref-type="bibr" rid="article-86483.r29">[29]</xref>&#x000a0;Studies&#x000a0;recommend using PCC over activated PCC (factor eight inhibitor bypass activity [FEIBA]) and recombinant factor VIIa because their prothrombotic potential may be higher than that of PCC.<xref ref-type="bibr" rid="article-86483.r12">[12]</xref>&#x000a0;</p>
        <p><bold>Resumption of the drug after bleeding</bold>:&#x000a0;In patients experiencing major bleeding, a careful reassessment of the risks and benefits of reinitiating anticoagulation is necessary.<xref ref-type="bibr" rid="article-86483.r30">[30]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-86483.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>NOACs like rivaroxaban have several benefits over warfarin, including faster time to achieve the effect, rapid onset of action,&#x000a0;predictable pharmacokinetics and pharmacodynamics, fewer documented food and drug interactions, lack of need for routine INR monitoring, and improved patient satisfaction.<xref ref-type="bibr" rid="article-86483.r7">[7]</xref>&#x000a0;[Level 3] Rivaroxaban is replacing warfarin as a choice of oral anticoagulants as warfarin has a narrow therapeutic index, has interaction with food or drug acting via CYP isoenzyme inhibiting or inducing pathway, needs frequent lab monitoring, and has a high bleeding risk profile.</p>
        <p>The major adverse effect of this drug is bleeding; hence, a thorough assessment of the patient is necessary before initiating this drug. The medical history of patients must rule out bleeding disorders, unstable blood pressure, chronic liver disease, chronic kidney disease, or anti-phospholipid antibody syndrome. Surgical history is necessary to rule out any heart valve replacements because such patients will benefit from taking warfarin. A drug history can rule out concomitant use of NSAIDs (nonsteroidal anti-inflammatory drugs), clopidogrel, and other blood thinners because such patients have increased bleeding risk. Before starting this drug, the patient must receive screening for bleeding and coagulation profile and hepatic or renal impairment.&#x000a0;A patient must receive counsel not to stop taking this drug without talking to the doctor as it may raise the chance of blood clots. Caution is necessary when performing&#x000a0;any spinal or epidural procedure because such patients are more likely to have a bleed around the spine, and the patient must have monitoring for signs of nerve problems like pain, weakness, numbness or tingling, paralysis, or loss of bladder or bowel control after the procedure. The patient must understand that they may bleed easily while on this drug and need to avoid cuts and injury and to watch out for signs of bleeding like vomiting or coughing blood, bleeding from gums, dark stools or vaginal bleeding, headache or dizziness, and bleeding that takes a long time to stop.&#x000a0;</p>
        <p>If a patient misses a 15 mg dose, tell the patient to immediately take the missed dose and&#x000a0;return to the normal daily dosing. If a patient misses a 2.5 mg dose, then the patient is asked to skip the missed dose and start with normal dosing from the next day. When the procedure/surgery is elective, stop rivaroxaban therapy at least 24 hours prior to the procedure or at least 48 hours in advance of procedures carrying an increased bleeding risk.&#x000a0;In patients requiring emergency surgery who have had&#x000a0;no bleeding events, studies do not recommend the prophylactic use of hemostatic blood products. After the procedure, rivaroxaban therapy should restart at the same dose, following adequate hemostasis (e.g., 24 hours after surgery).<xref ref-type="bibr" rid="article-86483.r11">[11]</xref></p>
        <p>The provision of prophylaxis to&#x000a0;patients&#x000a0;admitted for elective total knee replacement surgery has been proposed as an effective strategy to reduce the incidence of venous thromboembolism. Single prophylaxis strategies with oral factor Xa inhibitor are more effective in preventing deep vein thrombosis in the elective total knee replacement population than combination strategies (with anticoagulants and anti-platelets), with&#x000a0;rivaroxaban&#x000a0;being the most effective.<xref ref-type="bibr" rid="article-86483.r31">[31]</xref>&#x000a0;[Level 1]</p>
        <p>The efficacy and safety of rivaroxaban for patients with nonvalvular AF were assessed in a randomized, double-blind phase III trial (ROCKET AF).<xref ref-type="bibr" rid="article-86483.r11">[11]</xref>&#x000a0;The primary efficacy (a stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) endpoints from the ROCKET AF trial (Rivaroxaban&#x000a0;Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) were different among participants with WRF taking&#x000a0;rivaroxaban&#x000a0;and those taking warfarin.<xref ref-type="bibr" rid="article-86483.r32">[32]</xref>&#x000a0;Among patients with on-treatment WRF,&#x000a0;rivaroxaban&#x000a0;correlated with lower rates of stroke and systemic embolism than warfarin, without increasing the composite bleeding endpoint. [Level 1]<xref ref-type="bibr" rid="article-86483.r32">[32]</xref>&#x000a0;</p>
        <p>The cardiovascular outcomes for people using anticoagulation strategies&#x000a0;in patients with stable coronary artery disease or peripheral artery disease (PAD) resulted in a 24% reduction in the primary endpoint of cardiovascular death, stroke, or myocardial infarction and an 18% reduction in mortality.&#x000a0;Rivaroxaban&#x000a0;alone did not produce any additional benefit compared with aspirin. The combination therapy with rivaroxaban and aspirin reduced significant adverse limb events, including amputation, in patients with PAD. Based on these results, the addition of&#x000a0;rivaroxaban&#x000a0;to aspirin is expected to substantially reduce morbidity and mortality in patients with stable coronary or PAD&#x000a0;(Level 1).<xref ref-type="bibr" rid="article-86483.r33">[33]</xref>&#x000a0;</p>
        <p>Rivaroxaban is on the FDA Pregnancy&#x000a0;Category&#x000a0;C list. There is limited data available on pregnant women and lactating mothers, so the risk-benefit ratio requires assessment while initiating this drug.&#x000a0;Rivaroxaban falls under the list of drugs in the 2015 American Geriatrics Society Beers Criteria for non&#x02013;anti-infective medications to be avoided or have dose reductions with varying levels of kidney function in older adults.<xref ref-type="bibr" rid="article-86483.r34">[34]</xref>&#x000a0;</p>
        <p>Given the bleeding risk of rivaroxaban, an interprofessional team approach is necessary to ensure optimal therapeutic results while limiting and eliminating adverse effects and interactions. This team includes all clinicians, specialists, mid-level practitioners, nurses, and pharmacists, who must coordinate their activities and engage in open communication to ensure proper patient care with rivaroxaban, as with any anticoagulant therapy. [Level 5]</p>
      </sec>
      <sec id="article-86483.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=86483&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=86483">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/86483/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=86483">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-86483.s11">
        <title>References</title>
        <ref id="article-86483.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>BMC Pharmacol Toxicol</source>
            <year>2018</year>
            <month>May</month>
            <day>02</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">29720261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunk</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McShane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palkimas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gail Macik</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Direct oral anticoagulants in hypercoagulable states.</article-title>
            <source>J Thromb Thrombolysis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-85</page-range>
            <pub-id pub-id-type="pmid">27632140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shatzel</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Crapster-Pregont</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deloughery</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases.</article-title>
            <source>Thromb Haemost</source>
            <year>2016</year>
            <month>Aug</month>
            <day>01</day>
            <volume>116</volume>
            <issue>2</issue>
            <fpage>397</fpage>
            <page-range>397-400</page-range>
            <pub-id pub-id-type="pmid">27075620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linkins</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Aug</month>
            <day>31</day>
            <volume>130</volume>
            <issue>9</issue>
            <fpage>1104</fpage>
            <page-range>1104-1113</page-range>
            <pub-id pub-id-type="pmid">28646118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavender</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Toda Kato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Plotnikov</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Amuch&#x000e1;stegui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oude Ophuis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Hessen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mega</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.</article-title>
            <source>Eur Heart J Acute Cardiovasc Care</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>468</fpage>
            <page-range>468-74</page-range>
            <pub-id pub-id-type="pmid">25318481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samama</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.</article-title>
            <source>Thromb Res</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>127</volume>
            <issue>6</issue>
            <fpage>497</fpage>
            <page-range>497-504</page-range>
            <pub-id pub-id-type="pmid">20888031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mujer</surname>
                <given-names>MTP</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Atti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dimaandal</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shrotriya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gundabolu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dhakal</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.</article-title>
            <source>Adv Hematol</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>7636104</fpage>
            <pub-id pub-id-type="pmid">32231703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubitza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Becka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mueck</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>10</issue>
            <fpage>2757</fpage>
            <page-range>2757-65</page-range>
            <pub-id pub-id-type="pmid">18715524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubitza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Becka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wensing</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Voith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zuehlsdorf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>12</issue>
            <fpage>873</fpage>
            <page-range>873-80</page-range>
            <pub-id pub-id-type="pmid">16328318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Raskob</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spiro</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>De Sanctis</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Argenti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Albanese</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lipardi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barnathan</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.</article-title>
            <source>Thromb Haemost</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>120</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-524</page-range>
            <pub-id pub-id-type="pmid">31975354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Norrving</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Turpie</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2014</year>
            <volume>10</volume>
            <fpage>101</fpage>
            <page-range>101-14</page-range>
            <pub-id pub-id-type="pmid">24648742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turpie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Llau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Norrving</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.</article-title>
            <source>Thromb Haemost</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>108</volume>
            <issue>5</issue>
            <fpage>876</fpage>
            <page-range>876-86</page-range>
            <pub-id pub-id-type="pmid">23014816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Kr&#x000f6;ll</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban.</article-title>
            <source>Am J Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>130</volume>
            <issue>9</issue>
            <fpage>1024</fpage>
            <page-range>1024-1032</page-range>
            <pub-id pub-id-type="pmid">28601546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Horsmans</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Larrey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maddrey</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.</article-title>
            <source>Drug Saf</source>
            <year>2011</year>
            <month>Mar</month>
            <day>01</day>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-52</page-range>
            <pub-id pub-id-type="pmid">21332248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mueck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kubitza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Becka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>455</fpage>
            <page-range>455-66</page-range>
            <pub-id pub-id-type="pmid">23305158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lameijer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aalberts</surname>
                <given-names>JJJ</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review.</article-title>
            <source>Thromb Res</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>169</volume>
            <fpage>123</fpage>
            <page-range>123-127</page-range>
            <pub-id pub-id-type="pmid">30036784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yakuwa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamatani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murashima</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rivaroxaban Concentration in Breast Milk During Breastfeeding: A Case Study.</article-title>
            <source>Breastfeed Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>748</fpage>
            <page-range>748-751</page-range>
            <pub-id pub-id-type="pmid">31746638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forbes</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Polasek</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>319</fpage>
            <page-range>319-328</page-range>
            <pub-id pub-id-type="pmid">29593860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raval</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Diaz-Sandoval</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Washam</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Zazulia</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SP</given-names>
              </name>
              <collab>American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research</collab>
            </person-group>
            <article-title>Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Mar</month>
            <day>07</day>
            <volume>135</volume>
            <issue>10</issue>
            <fpage>e604</fpage>
            <page-range>e604-e633</page-range>
            <pub-id pub-id-type="pmid">28167634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice.</article-title>
            <source>Int J Lab Hematol</source>
            <year>2017</year>
            <month>May</month>
            <volume>39 Suppl 1</volume>
            <fpage>31</fpage>
            <page-range>31-36</page-range>
            <pub-id pub-id-type="pmid">28447413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douxfils</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ageno</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Samama</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lessire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ten Cate</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dogn&#x000e9;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mullier</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.</article-title>
            <source>J Thromb Haemost</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-219</page-range>
            <pub-id pub-id-type="pmid">29193737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomaselli</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dobesh</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Florido</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hucker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mess&#x000e9;</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sarode</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siegal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>19</day>
            <volume>70</volume>
            <issue>24</issue>
            <fpage>3042</fpage>
            <page-range>3042-3067</page-range>
            <pub-id pub-id-type="pmid">29203195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majeed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000c5;gren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holmstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bruzelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaireti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Odeberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hempel</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frisk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Oct</month>
            <day>12</day>
            <volume>130</volume>
            <issue>15</issue>
            <fpage>1706</fpage>
            <page-range>1706-1712</page-range>
            <pub-id pub-id-type="pmid">28835439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Makris</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The reversal of anticoagulation in clinical practice&#x02002;.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <page-range>314-319</page-range>
            <pub-id pub-id-type="pmid">30072557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Triller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Cott</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaatz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.</article-title>
            <source>Am J Hematol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>697</fpage>
            <page-range>697-709</page-range>
            <pub-id pub-id-type="pmid">30916798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awad</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Cocchio</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.</article-title>
            <source>P T</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>696</fpage>
            <page-range>696-701</page-range>
            <pub-id pub-id-type="pmid">24391389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reynolds</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.</article-title>
            <source>J Pharm Pract</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>755</fpage>
            <page-range>755-760</page-range>
            <pub-id pub-id-type="pmid">32089040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eerenberg</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kamphuisen</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Sijpkens</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Meijers</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Buller</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Oct</month>
            <day>04</day>
            <volume>124</volume>
            <issue>14</issue>
            <fpage>1573</fpage>
            <page-range>1573-9</page-range>
            <pub-id pub-id-type="pmid">21900088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nitzki-George</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Caprini</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Current state of knowledge on oral anticoagulant reversal using procoagulant factors.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>841</fpage>
            <page-range>841-55</page-range>
            <pub-id pub-id-type="pmid">23695644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steffel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Potpara</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Albaladejo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Desteghe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haeusler</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Oldgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reinecke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roldan-Schilling</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rowell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sinnaeve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Heidb&#x000fc;chel</surname>
                <given-names>H</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Apr</month>
            <day>21</day>
            <volume>39</volume>
            <issue>16</issue>
            <fpage>1330</fpage>
            <page-range>1330-1393</page-range>
            <pub-id pub-id-type="pmid">29562325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dawoud</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cobb</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Rossiter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharpin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stansby</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis.</article-title>
            <source>Lancet Haematol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>e530</fpage>
            <page-range>e530-e539</page-range>
            <pub-id pub-id-type="pmid">31444124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fordyce</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hellkamp</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lokhnygina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Breithardt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MR</given-names>
              </name>
              <collab>ROCKET AF Steering Committee and Investigators</collab>
            </person-group>
            <article-title>On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Jul</month>
            <day>05</day>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-47</page-range>
            <pub-id pub-id-type="pmid">27358435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhagirath</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.</article-title>
            <source>Future Cardiol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>443</fpage>
            <page-range>443-453</page-range>
            <pub-id pub-id-type="pmid">30417662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86483.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foody</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>American Geriatrics Society Beers Criteria and Anticoagulant Use in Older Adults With Renal Impairment.</article-title>
            <source>Kidney Int Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>222</fpage>
            <page-range>222-223</page-range>
            <pub-id pub-id-type="pmid">29340340</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
